SEC Comment Letter 0000000000-25-001594 to Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc.
Date: Feb. 12, 2025 · CIK: 0001857044 · Accession: 0000000000-25-001594
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284863
Letter
February 12, 2025 Jeffrey A. Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Re:Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Filed February 12, 2025 File No. 333-284863 Dear Jeffrey A. Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel, Esq.
Show Raw Text
February 12, 2025
Jeffrey A. Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed February 12, 2025
File No. 333-284863
Dear Jeffrey A. Meckler:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.